In fact, the selectivity of CCR8 for intratumoral Treg cells is remarkable and warrants a more detailed discussion about potential safety concerns vis-à-vis approved antibody-based drugs that are widely used in current cancer therapies. This evidence concerns the gene CCR8 and cancer.